Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: A systematic literature review

Thyroid

Volumn 23, Issue 4, 2013, Pages 392-407

  Anderson, Roger T ^a   Linnehan, John E ^b   Tongbram, Vanita ^b   Keating, Karen ^c   Wirth, Lori J ^d  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Oxford Outcomes ^*  (United States)

^c Global Biologics Research   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AG 6013736; ANTINEOPLASTIC AGENT; AXITINIB; BORTEZOMIB; CAPECITABINE; CEDIRANIB; CELECOXIB; DOXORUBICIN; EVEROLIMUS; GEFITINIB; IROFULVEN; LENALIDOMIDE; LENVATINIB; MOTESANIB; PANOBINOSTAT; PASIREOTIDE; PAZOPANIB; RADIOACTIVE IODINE; ROMIDEPSIN; ROSIGLITAZONE; SELUMETINIB; SORAFENIB; SUNITINIB; TANESPIMYCIN; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VORINOSTAT;

ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; DIFFERENTIATED THYROID CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INTERVENTION STUDY; MONOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; PROTEIN KINASE INHIBITORS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84875700950     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0520     Document Type: Review

References (57)

1. American Cancer Society. Thyroid Cancer. Available at: www.cancer.org/acs/groups/cid/documents/webcontent/003144-df.pdf (last accessed on February 26, 2013).
2. Nixon IJ, Whitcher MM, Palmer FL, Tuttle RM, Shaha AR, Shah JP, Patel SG, Ganly I 2012 The Impact of Distant Metastases at Presentation on Prognosis in Patients with Differentiated Carcinoma of the Thyroid Gland. Thyroid 22:884-889.
3. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism 91:2892-2899.
4. Berger A, Edelsberg J, Chung K, Ngyuyen A, Stepan D, Oster G 2007 Healthcare (HC) utilization and costs in patients (pts) with newly diagnosed metastatic thyroid cancer (MTC). Abstract presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5. Abstract no. 17082.
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
6. Capdevila J, Argiles G, Rodriguez-Frexinos V, Nunez I, Tabernero J 2010 New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era. Discov Med 9:153-162.
7. Schlumberger M, Lacroix L, Russo D, Filetti S, JM B 2007 Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 3:260-269.
8. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli J, Fragu P, Lumbroso J, Caillou B, Parmentier C 1986 Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63:960-967.
9. Carter WB, Tourtelot JB, Savell JG, Lilienfeld H 2011 New treatments and shifting paradigms in differentiated thyroid cancer management. Cancer Control 18:96-103. Pharmacia & Upjohn Company Division Of Pfizer Inc.
10. Doxorubicin Hydrochloride for Injection: May 2010 [package insert]. Available at: www.accessdata.fda.gov/drugs atfda-docs/label/2010/050467s070lbl. pdf (last accessed on October 24, 2012).
11. Haugen BR 1999 Management of the patient with progressive radioiodine non-responsive disease. Seminars in surgical oncology 16:34-41.
12. Argiris A, Agarwala SS, Karamouzis MV, Burmeister LA, Carty SE 2008 A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Investigational New Drugs 26:183-188.
13. Shimaoka K, Schoenfeld DA, Dewys WD, Creech RH, Deconti R 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160.
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma v.3.2012. Available at: www.nccn.org/ professionals/physician-gls/f-guidelines.asp#site (last accessed on October 24, 2012).
15. Elsevier B.V. Embase: Journals Coverage. Available at www.embase.com/info/what-is-embase/coverage (last accessed on August 17, 2012).
16. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Go'mez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ 2012 Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. The Lancet Oncology 13:897-905.
17. Chen L, Shen Y, Luo Q, Yu Y, Lu H, Zhu R 2011 Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. Thyroid 21:119-124.
18. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R, Nutting CM 2011 Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population. Eur J Endocrinol 165:315-322.
19. Kloos RT, Shah MH, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684.
20. Duntas LH, Vlassopoulou V, Boutsiadis A, Mantzou E, Anapliotou M, Tsatsoulis A 2011 Sorafenib in the treatment of radioiodine refractory thyroid cancer. A multicenter phase II study. Abstract presented at the 35th Annual Meeting of the European Thyroid Association, Krakow, Poland, September 10-14. Abstract no. P03.
21. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719.
22. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161:923-931.
23. Brose MS, Troxel AB, Puttaswamy K, Ma C, Keefe SM, Chalain AA, Fraker DL, Mandel SJ, Lee WM, Feldman MD, Loevner LA, O'Dwyer PJ 2009 Measurements of outcome of a phase II study of sorafenib for advanced thyroid cancer. Abstract presented at the 80th Annual Meeting of the American Thyroid Association, Palm Beach, FL, September 23-27. Short call poster 27.
24. Keefe SM, Troxel AB, Rhee S, Puttaswamy K, O'Dwyer PJ, Loevner LA,Mandel SJ, BroseMS2011 Phase II trial of sorafenib in patients with advanced thyroid cancer. Abstract presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7. Abstract no. 5562.
25. Cohen EEW, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, KaneMA, Sherman E, Kim S, Bycott P, TortoriciM, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 26:4708-4713.
26. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ 2008 A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18:317-323.
27. Sherman SI, Jarzab B, Cabanillas ME, Licitra LF, Pacini F, Martins R, Robinson B, Ball D, McCaffrey J, Shah MH, Bodenner D, Allison R, Newbold K, Elisei R, O'Brien JP, Schlumberger M 2011 A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)- refractory differentiated thyroid cancer (DTC). Abstract presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7. Abstract no. 5503.
28. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. New England Journal of Medicine 359:31-42.
29. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C 2010 Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. The Lancet Oncology 11:962-972.
30. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG 2010 Phase II study of daily sunitinib in FDG-ET-ositive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clinical Cancer Research 16:5260-5268.
31. Sherman EJ, Ho AL, Fury MG, Baxi SS, Haque S, Korte SH, Smith-Marrone S, Xiao H, Ghossein RA, Fagin JA, Pfister DG 2012 A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. Abstract presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5. Abstract no. 5514.
32. Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH 2006 Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 91:2201-2204.
33. Kebebew E, Lindsay S, Clark OH, Woeber KA, Hawkins R, Greenspan FS 2009 Results of rosiglitazone therapy in patients with thyroglobulin-ositive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 19:953-956.
34. Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EEW 2012 Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY- 142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 18:2056-2065.
35. Ain KB, Lee C, Williams KD 2007 Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 17:663-670.
36. Sherman EJ, Ho AL, Haque S, Tuttle RM, Ghossein RA, Schoder H, Baum MS, Kelly K, Chen AP, Shaha AR, Pfister DG 2011 A phase II study of VEGF trap in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. Abstract presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7. Abstract no. 5566.
37. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, Grever M, Villalona-Calero M, Shah MH 2009 Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodinerefractory thyroid carcinoma. J Clin Endocrinol Metab 94:164-170.
38. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655.
39. Dana-Farber Cancer Institute 2000- RAD001 for patients with radioiodine refractory thyroid cancer. In: Clinical- Trials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ ct2/show/NCT00936858 (NLM Identifier: NCT00936858; cited August 17, 2012).
40. Leiden University Medical Center 2000- Everolimus in treating patients with progressive or recurrent, unresectable, or metastatic thyroid cancer. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/NCT01118065 (NLM Identifier: NCT01118065; cited August 17, 2012).
41. Memorial Sloan-Kettering Cancer Center 2000- Evaluating the combination of everolimus and sorafenib in the treatment of radioactive iodine refractory thyroid cancer. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/ NCT01141309 (NLM Identifier: NCT01141309; cited August 17, 2012).
42. Yonsei University 2000- Everolimus in treating patients with locally advanced or metastatic thyroid cancer. In: Clinical- Trials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/NCT01164176 (NLM Identifier: NCT01164176; cited August 17, 2012).
43. Emory University 2000- A trial of pasireotide and everolimus in adult patients with radioiodine-refractory differentiated and medullary thyroid cancer. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/NCT01270321 (NLM Identifier: NCT01270321; cited August 17, 2012).
44. Bayer 2000- Nexavar- versus placebo in locally advanced/metastatic RAI-refractory differentiated thyroid cancer. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from: http://clinical trials.gov/ct2/show/NCT00984282 (NLM Identifier: NCT- 00984282; cited August 17, 2012).
45. Memorial Sloan-Kettering Cancer Center 2000- Combination of temsirolimus and sorafenib in the treatment of radioactive iodine refractory thyroid cancer. In: Clinical- Trials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/NCT01025453 (NLM Identifier: NCT01025453; cited August 17, 2012).
46. University Hospital Bordeaux 2000- Thyroid cancer and sunitinib (THYSU). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/NCT00510640 (NLM Identifier: NCT00510640; cited August 17, 2012).
47. University of Chicago 2000- Sunitinib in treating patients with thyroid cancer that did not respond to iodine I 131 and cannot be removed by surgery. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/NCT00 381641 (NLM Identifier: NCT00381641; cited August 17, 2012).
48. Washington Hospital Center 2000- Sutent adjunctive treatment of differentiated thyroid cancer (IIT sutent). In: ClinicalTrials. gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/NCT00668811 (NLM Identifier: NCT00668811; cited August 17, 2012).
49. Eisai Inc 2000- A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of lenvatinib (E7080) in 131I-refractory differentiated thyroid cancer. In: Clinical- Trials.gov. Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/ NCT01321554 (NLM Identifier: NCT01321554; cited August 17, 2012).
50. Busaidy NL, Cabanillas ME 2012 Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res 2012:Article ID 618985.
51. Kojic KL, Kojic SL, Wiseman SM 2012 Differentiated thyroid cancers: a comprehensive review of novel targeted therapies. Expert Rev Anticancer Ther 12:345-357.
52. O'Neill CJ, Oucharek J, Learoyd D, Sidhu SB 2010 Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 15:146-156.
53. Perez CA, Arango BA, Velez M, Raez LE, Santos ES 2012 Emerging role of multikinase inhibitors for refractory thyroid cancer. Biologics 6:257-265.
54. Ball D, Sherman S, Jarzab B, Cabanillas M, Licitra L, Pacini F, Martins RG, Robinson B, McCaffrey JC, Shah MH, Bodenner D, Allison R, Newbold K, Elisei R, Sachdev P, Kadowaki T, Funahashi Y, O'Brien JP, Schlumberger M 2011 A Phase II Trial of the Multi-Targeted Kinase Inhibitor Lenvatinib (E7080) in Advanced Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer (DTC): Correlation of Treatment Outcomes with Tumor Genetic Analysis, Serum Biomarkers and Pharmacokinetics. Abstract presented at the 81st Annual Meeting of the American Thyroid Association, Indian Wells, CA, October 26-30. Oral Presentation 3.
55. Fukahori M, Yoshida A, Hayashi H, Yoshihara M, Matsukuma S, Sakuma Y, Koizume S, Okamoto N, Kondo T, Masuda M, Miyagi Y 2012 The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid 22:683-689.
56. Ho AL, Leboeuf R, Grewal RK, Sherman EJ, Deandreis D, Pentlow KS, Tuttle RM, Fury MG, Ricarte-Filho JCM, Pfister DG, Larson SM, Fagin JA 2012 Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib. Abstract presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5. Abstract no. 5509.
57. Memorial Sloan-Kettering Cancer Center 2000- Reacquisition of radioactive iodine (RAI) uptake of RAI-refractory metastatic thyroid cancers by pretreatment with the selective MEK inhibitor AZD6244. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/NCT00970359 (NLM Identifier: NCT00970359; cited August 17, 2012).